Northeastern University

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Benjamin M. Beneski has been promoted to Senior Vice President and Chief Technical Officer (CTO). Mr. Beneski succeeds Tim Moore, who will be stepping down at the end of February after two years with the Company. Mr. Moore’s impactful career spans nearly a decade of collaboration with the broader team, during which he made significant contributions to Allogene and the field of cell and gene therapy. As CTO, Mr. Beneski will oversee Allogene’s technical operations, leveraging his extensive expertise in biologics manufacturing, process development, and operational leadership to carry on the work of Mr. Moore and further advance the company’s groundbreaking allogeneic cell therapy programs. "We are delighted to announce Ben's promotion to Chief Technical Officer," said David Chang, M.D., Ph.D., President, CEO, and Co-Founder of Allogene. "His leadership and dedication have been instrumental in shaping our manufacturing strategy and capabilities. Ben’s proven track record of delivering results, creating innovative solutions, and building high-performing teams makes him uniquely qualified to lead our technical operations into the next phase." Dr. Chang continued, "Many of us at Allogene have had the distinct privilege of working alongside Tim for nearly a decade. He joined us during a crucial time, bringing expertise and leadership that were instrumental in getting us to where we are today. We are deeply grateful for Tim's unwavering commitment, transformative contributions, and exceptional dedication to mentoring and empowering the next generation of leaders. Tim will forever remain a dear friend and an enduring part of Allogene's legacy." Mr. Beneski joined Allogene in 2019 as Executive Director and Plant Manager, leading the design, construction, and startup of Cell Forge 1, the company’s state-of-the-art manufacturing facility. Over the years, he has held increasingly senior roles, including Vice President of Manufacturing and Vice President of Product Development and Manufacturing. In these roles, he led the development of next-generation platforms, successfully managed internal and external manufacturing networks, and drove key initiatives supporting IND submissions and commercial readiness. Mr. Beneski’s career spans over two decades in biologics manufacturing and technical operations, including leadership roles at Vir Biotechnology and Amgen. He holds a Master’s in Business Administration from Northeastern University and a Bachelor of Engineering in Chemical Engineering from Stevens Institute of Technology. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “will,” “advance,” “goal,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for treating cancer and autoimmune disease, the ability to advance allogeneic cell therapy programs or develop next generation platforms, or the ability to develop a pipeline of “off-the-shelf” CAR T cell product candidates that deliver readily available cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and whether we will ultimately obtain regulatory approval. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ is a trademark of Allogene Therapeutics, Inc. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy OfficerChristine.Cassiano@allogene.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be965d76-f1a3-4452-bb4d-9ba99d7b1962

Seasoned Business Executives Join Rethink to Lead Continued Success in Delivering Data-Driven Behavioral Health Solutions to Global Communities NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Rethink, the leading SaaS software and solutions provider in behavioral health, today announced that it has appointed Paul Bogonis as chief financial officer and Ewan Auguste as chief marketing officer. With more than 25 years of experience successfully building and leading companies with a focus on accelerating growth and increasing value to customers, Bogonis will oversee all finance functions for the company. Bogonis most recently served as chief financial officer for Greenhouse Software, with prior experience in finance leadership roles at companies such as Bottomline Technologies, Empirix and QL2. Bogonis earned a Bachelor's degree in Accounting from Northeastern University and an M.B.A. from Boston University's Questrom School of Business. "I am excited to join Rethink at such a pivotal time in the company's growth journey," said Bogonis. "Rethink has established itself as a market leader with a solid foundation and incredible people. I'm looking forward to contributing to the next chapter of growth, building strong relationships with the Rethink team, customers and investors, while driving financial and operational excellence across the organization." Auguste, who will lead all aspects of marketing for Rethink and its business lines, has spent the last 15 years developing creative marketing solutions to generate increased customer demand at some of the most well-known brands in the technology industry. Auguste most recently served as chief marketing officer for PlanSource, after successful posts in senior marketing roles at Adobe, Workfront and IBM. Auguste earned a Bachelor's degree in Computer Information Systems and an M.B.A from Washburn University. "This is a fantastic opportunity to lead a talented team, foster a culture of collaboration and drive innovative marketing strategies that champion neurodiversity," said Auguste. "As chief marketing officer, I look forward to contributing to the continued growth and success of Rethink, as well as making a positive impact on the lives of individuals and organizations we serve." About Rethink Rethink is a global health technology company providing cloud-based treatment tools, training, and clinical support to employers, educators, payors and behavioral health professionals. Rethink's award-winning solutions serve thousands of clients globally, including nearly one-third of the Fortune 100 and many of the country's largest public-school systems and health plans. Each of Rethink's award-winning solutions incorporates evidenced-based protocols, workflow automation and advanced data analytics to drive meaningful clinical outcomes and improved performance for customers and the communities that they serve. Visit rethinkfirst.com to learn more. SOURCE RethinkFirst WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CHICAGO, Dec. 4, 2024 /PRNewswire/ -- A new study found that injury rates among transgender women are significantly higher than injuries among cisgender women, based on radiological imaging. The findings will be presented today at the annual meeting of the Radiological Society of North America (RSNA). 'Cisgender' is a term used to describe people whose gender identity matches the sex they were assigned at birth, while 'transgender' describes people whose gender identity differs from the sex they were assigned at birth. "Transgender women have been reported to experience alarmingly high rates of violence," said lead researcher Rohan Chopra, an undergraduate student at Northeastern University in Boston and a research intern at the Trauma Imaging Research and Innovation Center (TIRIC) at Brigham and Women's Hospital. "They also frequently endure discrimination, hate crimes, psychological abuse and social isolation, which not only increases their vulnerability but also creates significant barriers in reporting violence and escaping abusive situations." The first-of-its-kind study, conducted by TIRIC, employs a case-control design to quantify and compare the burden of injuries evident on imaging between transgender women and a control group of cisgender women. For the study, researchers selected a cohort of 263 trans-female patients, aged 18 and older, from the Research Patient Data Registry. All patients had undergone at least one imaging exam at a Massachusetts General Brigham affiliated hospital. From the same registry, a control group was selected of 525 cisgender female control patients, matched for age, race and ethnicity, who also underwent at least one imaging exam. Among the transgender women, 67 (25.4%) sustained 141 injuries, compared to 77 (14.7%) of cisgender women who sustained 98 injuries. Transgender women in the study group suffered eight times as many head injuries as the controls, 36 times as many facial injuries and five times as many chest injuries. "Transgender women were five times more likely to undergo imaging in the emergency department compared to cisgender women and were nearly twice as likely to get imaged overnight and on weekends," Chopra said. "Most importantly, transgender women were three times as likely to sustain injuries compared to cisgender women." Of the 67 transgender women with injuries confirmed by a radiological exam, 41.8% (28 of 67) reported being involved in interpersonal violence and 28.4% (19 of 67) confirmed intimate partner violence (IPV). However, 25 (37.3%) of the 67 transgender patients were not screened for IPV. Two radiologists, blinded to the purpose of the study and the transgender status, were also asked to predict the likelihood of IPV based on the radiology reports. The radiologists correctly identified IPV in about one-third of the transgender individuals who reported it. "The significantly higher injury rates in transgender women, particularly to the head, face and chest, with frequent presentations to emergency departments indicate an elevated risk of violence and highlight gaps in preventive care," said Bharti Khurana, M.D., M.B.A., the study's principal investigator and founder and director of TIRIC. "By recognizing these patterns, radiologists can help identify at-risk patients and facilitate timely IPV screening and support for this vulnerable population." Other co-authors are Krishna Patel, M.P.H., Tatiana C. Rocha, M.D., Maria Duran-Mendicuti, M.D., Jessica C. Loftus, L.I.C.S.W., Jacqueline Savage Borne, L.I.C.S.W., Lauren Kourabas, L.I.C.S.W., Bernard Rosner, Ph.D., M.S., and Ole-Petter R. Hamnvik, M.D. Note: Copies of RSNA 2024 news releases and electronic images will be available online at RSNA.org/press24. RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org) For patient-friendly information on emergency radiology, visit RadiologyInfo.org. SOURCE Radiological Society of North America (RSNA) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED